Development of a human live attenuated West Nile infectious DNA vaccine: conceptual design of the vaccine candidate (Q38864403)

7 September 2017

Development of a human live attenuated West Nile infectious DNA vaccine: conceptual design of the vaccine candidate (English)

1 reference

7 September 2017

0 references

0 references

1 reference

1 reference

Vladimir Yamshchikov

1

1 reference

PubMed ID

26071925

7 September 2017

language of work or name

English

0 references

publication date

9 June 2015

1 reference

7 September 2017

1 reference

7 September 2017

484

1 reference

7 September 2017

59-68

1 reference

Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Current trends in West Nile virus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Japanese encephalitis and dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A highly sensitive and versatile virus titration assay in the 96-well microplate format

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Biological properties of chimeric West Nile viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Primary structure of the West Nile flavivirus genome region coding for all nonstructural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Sequence analysis of the viral core protein and the membrane-associated proteins V1 and NV2 of the flavivirus West Nile virus and of the genome sequence for these proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Nucleotide sequence of the 5'-terminal untranslated part of the genome of the flavivirus West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Novel strategies to improve DNA vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

West Nile virus inhibits the signal transduction pathway of alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Identifying protective dengue vaccines: guide to mastering an empirical process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Resistance to Alpha/Beta Interferon Is a Determinant of West Nile Virus Replication Fitness and Virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Short- and long-term changes in gene expression mediated by the activation of TLR9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Mutations in the Yellow Fever Virus Nonstructural Protein NS2A Selectively Block Production of Infectious Particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A Single Amino Acid Substitution in the West Nile Virus Nonstructural Protein NS2A Disables Its Ability To Inhibit Alpha/Beta Interferon Induction and Attenuates Virus Virulence in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Call to action for dengue vaccine failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A 'minimal' approach in design of flavivirus infectious DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Analyses of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Differential induction of antiviral effects against West Nile virus in primary mouse macrophages derived from flavivirus-susceptible and congenic resistant mice by alpha/beta interferon and poly(I-C).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Flavivirus DNA vaccines--good science, uncertain future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Systematic analysis of viral genes responsible for differential virulence between American and Australian West Nile virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

DNA vaccination in the skin using microneedles improves protection against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Complete nucleotide sequence of the Japanese encephalitis virus genome RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Terminal sequences of the genome and replicatioe-form RNA of the flavivirus west nile virus: absence of poly(A) and possible role in RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Sequence analysis of the membrane protein V3 of the flavivirus West Nile virus and of its gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

Studies on virus-specific nucleic acids synthesized in vertebrate and mosquito cells infected with flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

West Nile Virus Infection in the Golden Hamster (Mesocricetus auratus): A Model for West Nile Encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

The suitability of yellow fever and Japanese encephalitis vaccines for immunization against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E. coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

An infectious clone of the West Nile flavivirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2015.04.027

10.1016/J.VIROL.2015.04.027

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

26071925